DRUG Bright Minds Biosciences Inc.
USHealthcareAs of 2026-07-10 16:00
Why DRUG matters now
Bright Minds Biosciences Inc. (DRUG) is a US stock in Healthcare. The latest InvestLog snapshot shows $77.84 with -0.46% on the session and $604.2M in market capitalization; recent performance reads 1-month -18.62% and YTD -22.27%.
The latest financial table shown here is Q2 2026, with revenue of $0.00, net income of $-10.6M, and EPS of $-1.12. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.0%.
The latest indexable market news headline is "Bright Minds Biosciences to Present at Jefferies Global Healthcare Conference" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $146.00; recent insider activity includes Cormorant Asset Management, LP filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
2.73
P/S
0.00
EV/EBITDA
-11.86
DCF Value
$8.47
FCF Yield
-3.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-20.7%
ROA
-8.8%
ROIC
-10.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $0.00 | $-10.6M | $-1.12 |
| Q1 2026 | $0.00 | $-7.6M | $-0.97 |
| Q4 2025 | $0.00 | $-4.1M | $-0.41 |
| FY 2025 | $0.00 | $-12.2M | $-1.78 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$159.50
Target (Median)
$146.00
Target Range
$126.00 - $220.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
CA
Exchange
—
Beta
-0.11
Bright Minds Biosciences Inc. is a preclinical biotechnology firm dedicated to creating serotonin-based therapies. Its primary goal is to enhance the well-being of individuals suffering from severe and life-altering conditions. The company's development pipeline includes selective agonists for the 5-HT2C, 5-HT2A, and combined 5-HT2C/A serotonin receptors, which are being explored for potential treatments in epilepsy, pain management, and neuropsychiatric disorders. Bright Minds maintains strategic collaborations with the National Institutes of Health (NIH) for epilepsy research, the University of Texas Medical Branch (UTMB) for impulse control disorders like binge eating, and the Medical College of Wisconsin. The company, incorporated in 2019, operates from its headquarters in Vancouver, Canada.